Annual CFO
-$24.10 M
+$3.54 M+12.80%
31 December 2023
Summary:
Moleculin Biotech annual cash flow from operations is currently -$24.10 million, with the most recent change of +$3.54 million (+12.80%) on 31 December 2023. During the last 3 years, it has fallen by -$5.15 million (-27.18%). MBRX annual CFO is now -540.13% below its all-time high of -$3.77 million, reached on 31 December 2016.MBRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.11 M
-$164.00 K-2.76%
30 September 2024
Summary:
Moleculin Biotech quarterly cash flow from operations is currently -$6.11 million, with the most recent change of -$164.00 thousand (-2.76%) on 30 September 2024. Over the past year, it has dropped by -$706.00 thousand (-13.06%). MBRX quarterly CFO is now -2007.93% below its all-time high of -$290.00 thousand, reached on 31 March 2016.MBRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$24.19 M
+$1.44 M+5.61%
30 September 2024
Summary:
Moleculin Biotech TTM cash flow from operations is currently -$24.19 million, with the most recent change of +$1.44 million (+5.61%) on 30 September 2024. Over the past year, it has dropped by -$85.00 thousand (-0.35%). MBRX TTM CFO is now -8240.00% below its all-time high of -$290.00 thousand, reached on 31 March 2016.MBRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MBRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -13.1% | -0.3% |
| 3 y3 years | -27.2% | -43.6% | -27.6% |
| 5 y5 years | -40.1% | -30.7% | -40.6% |
MBRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -27.2% | +12.8% | -43.6% | +23.6% | -27.6% | +16.2% |
| 5 y | 5 years | -40.1% | +12.8% | -95.7% | +23.6% | -41.8% | +16.2% |
| alltime | all time | -540.1% | +12.8% | -2007.9% | +23.6% | -8240.0% | +16.2% |
Moleculin Biotech Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.11 M(+2.8%) | -$24.19 M(-5.6%) |
| June 2024 | - | -$5.95 M(-11.4%) | -$25.62 M(+3.3%) |
| Mar 2024 | - | -$6.72 M(+24.2%) | -$24.80 M(+2.9%) |
| Dec 2023 | -$24.10 M(-12.8%) | -$5.41 M(-28.4%) | -$24.10 M(-7.1%) |
| Sept 2023 | - | -$7.55 M(+47.3%) | -$25.95 M(-0.1%) |
| June 2023 | - | -$5.13 M(-14.8%) | -$25.98 M(-10.0%) |
| Mar 2023 | - | -$6.02 M(-17.1%) | -$28.85 M(+4.4%) |
| Dec 2022 | -$27.64 M(+45.8%) | -$7.26 M(-4.2%) | -$27.64 M(+12.2%) |
| Sept 2022 | - | -$7.58 M(-5.3%) | -$24.64 M(+15.4%) |
| June 2022 | - | -$8.00 M(+66.5%) | -$21.35 M(+6.1%) |
| Mar 2022 | - | -$4.80 M(+12.8%) | -$20.13 M(+6.2%) |
| Dec 2021 | -$18.95 M(+6.6%) | -$4.26 M(-0.7%) | -$18.95 M(+6.4%) |
| Sept 2021 | - | -$4.29 M(-36.8%) | -$17.82 M(-5.7%) |
| June 2021 | - | -$6.78 M(+87.1%) | -$18.90 M(+10.8%) |
| Mar 2021 | - | -$3.62 M(+16.0%) | -$17.05 M(-4.0%) |
| Dec 2020 | -$17.77 M | -$3.12 M(-41.8%) | -$17.77 M(-8.0%) |
| Sept 2020 | - | -$5.37 M(+8.9%) | -$19.32 M(+11.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$4.93 M(+13.6%) | -$17.28 M(-2.3%) |
| Mar 2020 | - | -$4.34 M(-7.2%) | -$17.69 M(+2.9%) |
| Dec 2019 | -$17.20 M(+40.9%) | -$4.68 M(+40.6%) | -$17.20 M(+10.0%) |
| Sept 2019 | - | -$3.33 M(-37.8%) | -$15.63 M(+3.4%) |
| June 2019 | - | -$5.35 M(+39.0%) | -$15.12 M(+14.2%) |
| Mar 2019 | - | -$3.85 M(+23.7%) | -$13.24 M(+8.5%) |
| Dec 2018 | -$12.20 M(+66.6%) | -$3.11 M(+10.3%) | -$12.20 M(+6.3%) |
| Sept 2018 | - | -$2.82 M(-18.7%) | -$11.48 M(+11.8%) |
| June 2018 | - | -$3.47 M(+23.5%) | -$10.28 M(+17.6%) |
| Mar 2018 | - | -$2.81 M(+17.4%) | -$8.74 M(+19.3%) |
| Dec 2017 | -$7.32 M(+94.5%) | -$2.39 M(+48.4%) | -$7.32 M(+20.0%) |
| Sept 2017 | - | -$1.61 M(-16.6%) | -$6.10 M(+12.1%) |
| June 2017 | - | -$1.93 M(+38.9%) | -$5.44 M(+11.9%) |
| Mar 2017 | - | -$1.39 M(+19.0%) | -$4.87 M(+29.2%) |
| Dec 2016 | -$3.77 M | -$1.17 M(+22.9%) | -$3.77 M(+45.0%) |
| Sept 2016 | - | -$951.00 K(-29.8%) | -$2.60 M(+57.8%) |
| June 2016 | - | -$1.35 M(+367.2%) | -$1.65 M(+467.2%) |
| Mar 2016 | - | -$290.00 K | -$290.00 K |
FAQ
- What is Moleculin Biotech annual cash flow from operations?
- What is the all time high annual CFO for Moleculin Biotech?
- What is Moleculin Biotech quarterly cash flow from operations?
- What is the all time high quarterly CFO for Moleculin Biotech?
- What is Moleculin Biotech quarterly CFO year-on-year change?
- What is Moleculin Biotech TTM cash flow from operations?
- What is the all time high TTM CFO for Moleculin Biotech?
- What is Moleculin Biotech TTM CFO year-on-year change?
What is Moleculin Biotech annual cash flow from operations?
The current annual CFO of MBRX is -$24.10 M
What is the all time high annual CFO for Moleculin Biotech?
Moleculin Biotech all-time high annual cash flow from operations is -$3.77 M
What is Moleculin Biotech quarterly cash flow from operations?
The current quarterly CFO of MBRX is -$6.11 M
What is the all time high quarterly CFO for Moleculin Biotech?
Moleculin Biotech all-time high quarterly cash flow from operations is -$290.00 K
What is Moleculin Biotech quarterly CFO year-on-year change?
Over the past year, MBRX quarterly cash flow from operations has changed by -$706.00 K (-13.06%)
What is Moleculin Biotech TTM cash flow from operations?
The current TTM CFO of MBRX is -$24.19 M
What is the all time high TTM CFO for Moleculin Biotech?
Moleculin Biotech all-time high TTM cash flow from operations is -$290.00 K
What is Moleculin Biotech TTM CFO year-on-year change?
Over the past year, MBRX TTM cash flow from operations has changed by -$85.00 K (-0.35%)